CryoTherapeutics, focusing on the development, demonstration of clinical benefit, and early-stage commercialization of a proprietary cryotherapy system for use in the treatment of coronary artery disease that causes heart attacks, announces today that it has received additional funding of € 12.3 million.
Emperra's digital diabetes management solution ESYSTA among the five trends for the healthcare system of the future in the "Handelsblatt" newspaper:
Click here for the article!
Deutsches Tech-Start-up gewinnt ersten Preis bei der Medica
Auf der Medizintechnik-Messe Medica in Düsseldorf wurden zwei junge Tech-Firmen mit Preisen gewürdigt. Die Start-ups hoffen durch die Auszeichnung auf mehr Sichtbarkeit.
CEVEC and UCB sign agreement for the use of CEVEC’s ELEVECTA® AAV manufacturing technology in Gene Therapy
CEVEC Pharmaceuticals GmbH (CEVEC) today announced the signing of an agreement with UCB S.A. (UCB; Euronext: UCB) on the evaluation and use of CEVEC’s proprietary ELEVECTA® Technology for the research, development, and manufacturing of Adeno-Associated Virus (AAV) vectors for gene therapy applications.
CEVEC closes growth financing round to serve strong demand in viral vector technologies for cell and gene therapies
CEVEC Pharmaceuticals GmbH (CEVEC), the leading provider of high-performance cell technology for scalable manufacturing of advanced bio-therapeutics, today announced the successful closing of an internal growth financing round.
Congratulations to our portfolio company Emperra GmbH E-Health Technologies for the listing of their ESYSTA App as the first Diabetes DiGA and becoming the first broadly reimbursed digital diabetes solution in Germany. This is a major achievement and will help many diabetic patients in their daily life.
Implandata Ophthalmic Products, a digital health company with offices in Germany and San Diego, California has announced today that its EYEMATE-SC biosensor has obtained CE Mark. This device is used in conjunction with the breakthrough EYEMATE system for digitally enabled remote glaucoma monitoring and management.
With the successful completion of a second closing, Labforward adds >€3m to the Series B from January, bringing the total funds raised to >€8.5m. The majority of the new investment comes from the Fielmann Family Office.
Implandata Ophthalmic Products, a digital health company with offices in Germany and San Diego, California has announced today that its game-changing EYEMATE system for digitally enabled remote patient monitoring and management of glaucoma has obtained Breakthrough Device Designation (BDD) from the U.S. Food and Drug Administration (FDA).
People with glaucoma and eye doctors face a dilemma. On one hand, patients with glaucoma are at high risk of losing their eyesight if their disease progresses undetected and essential therapy adjustments are delayed. On the other hand, these typically elderly, vulnerable individuals are often hampered in seeing their doctor for office visits, particularly during a lockdown.